Nyamekye Obeng-Adjei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nyamekye Obeng-Adjei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aissata Ongoiba
Mali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali
2 shared publications - Boubacar Traore
Epidemiology laboratory, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Morocco
2 shared publications - Caroline O. Buckee
Department of Epidemiology, Harvard T.H. Chan School of Public Health
2 shared publications - Daniel B. Larremore
Department of Computer Science, University of Colorado Boulder, Boulder, CO, USA
2 shared publications - Kassoum Kayentao
Mali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali
2 shared publications - Louise Turner
Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, University of Copenhagen
2 shared publications
Latest Publications
- 18 June 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (12)
Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection
BACKGROUND: Malaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum –infected erythrocytes to the microvasculature mediated via specific interactions between P . falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria. METHODS: We evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission. RESULTS: Using longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes. CONCLUSION: This study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant–specific antibodies. TRIAL REGISTRATION: ClinicalTrials.gov NCT01322581. FUNDING: Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.
- 18 June 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (12)
Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection
BACKGROUND: Malaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum –infected erythrocytes to the microvasculature mediated via specific interactions between P . falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria. METHODS: We evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission. RESULTS: Using longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes. CONCLUSION: This study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant–specific antibodies. TRIAL REGISTRATION: ClinicalTrials.gov NCT01322581. FUNDING: Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.
- Open Access
Longitudinal analysis of naturally acquired antibodies to PfEMP1 CIDR domain variants and their association with malaria protection
Malaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum infected erythrocytes to the microvasculature mediated via specific interactions between PfEMP1 variant domains to host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria. We evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission. Using longitudinal data, we found that IgG to the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG to CIDRγ3 was associated with reduced prospective risk of febrile malaria and recurrent malaria episodes. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.
Open AccessLongitudinal analysis of naturally acquired antibodies to PfEMP1 CIDR domain variants and their association with malaria protection
Malaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum infected erythrocytes to the microvasculature mediated via specific interactions between PfEMP1 variant domains to host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria. We evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission. Using longitudinal data, we found that IgG to the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG to CIDRγ3 was associated with reduced prospective risk of febrile malaria and recurrent malaria episodes. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.